LC, Magaldi AJ. Aquaporin 2 expression increased by glucagon in normal rat inner medullary collecting ducts. Am J Physiol Renal Physiol 296: F54 -F59, 2009. First published October 1, 2008 doi:10.1152/ajprenal.90367.2008.-It is well known that Glucagon (Gl) is released after a high protein diet and participates in water excretion by the kidney, principally after a protein meal. To study this effect in in vitro perfused inner medullary collecting ducts (IMCD), the osmotic water permeability (Pf; m/s) at 37°C and pH 7.4 in normal rat IMCDs (n ϭ 36) perfused with Ringer/HCO 3 was determined. Gl (10 Ϫ7 M) in absence of Vasopressin (AVP) enhanced the Pf from 4.38 Ϯ 1.40 to 11.16 Ϯ 1.44 m/s (P Ͻ 0.01). Adding 10 Ϫ8 , 10 Ϫ7 , and 10 Ϫ6 M Gl, the Pf responded in a dose-dependent manner. The protein kinase A inhibitor H8 blocked the Gl effect. The specific Gl inhibitor, des-His 1 -[Glu 9 ] glucagon (10 Ϫ7 M), blocked the Glstimulated Pf but not the AVP-stimulated Pf. There occurred a partial additional effect between Gl and AVP. The cAMP level was enhanced from the control 1.24 Ϯ 0.39 to 59.70 Ϯ 15.18 fm/mg prot after Gl 10 Ϫ7 M in an IMCD cell suspension. The immunoblotting studies indicated an increase in AQP2 protein abundance of 27% (cont 100.0 Ϯ 3.9 vs. Gl 127.53; P ϭ 0.0035) in membrane fractions extracted from IMCD tubule suspension, incubated with 10 Ϫ6 M Gl. Our data showed that 1) Gl increased water absorption in a dosedependent manner; 2) the anti-Gl blocked the action of Gl but not the action of AVP; 3) Gl stimulated the cAMP generation; 4) Gl increased the AQP2 water channel protein expression, leading us to conclude that Gl controls water absorption by utilizing a Gl receptor, rather than a AVP receptor, increasing the AQP2 protein expression. glucagon; aquaporin 2; water transport; glucagon antagonist; vasopressin GLUCAGON IS A POLYPEPTIDE whose major physiological role is to participate in the regulation of blood sugar levels. Its action is mainly on hepatic glycogenolysis and gluconeogenesis. Even though the kidney is not considered to be the principal target organ for the action of glucagon, it has been known since 1957 (22) that this hormone enhances sodium excretion after intravenous administration to dogs. Other investigators have confirmed the natriuretic effect of glucagon by using different doses (9, 18, 19). In 1958, Sutherland et al. (23) showed that glucagon was able to produce glycogen breakdown in hepatocytes by stimulating adenylyl cyclase and cyclic adenosine monophosphate (cAMP).
glucagon; aquaporin 2; water transport; glucagon antagonist; vasopressin GLUCAGON IS A POLYPEPTIDE whose major physiological role is to participate in the regulation of blood sugar levels. Its action is mainly on hepatic glycogenolysis and gluconeogenesis. Even though the kidney is not considered to be the principal target organ for the action of glucagon, it has been known since 1957 (22) that this hormone enhances sodium excretion after intravenous administration to dogs. Other investigators have confirmed the natriuretic effect of glucagon by using different doses (9, 18, 19) . In 1958, Sutherland et al. (23) showed that glucagon was able to produce glycogen breakdown in hepatocytes by stimulating adenylyl cyclase and cyclic adenosine monophosphate (cAMP).
In 1976, Mulvehill et al. (15) demonstrated that glucagon produced a dose-dependent stimulation of adenylyl cyclase in cell-free preparations of human renal medullas. This finding showed that the effect of glucagon could be mediated by cAMP. In the 1980s, Bailly et al. (4) , by measuring glucagonsensitive adenylyl cyclase activity, showed that distal nephrons are highly responsive to this hormone, and Butlen et al. (7) , using [
125 I]glucagon, showed that the nephron has a specific receptor for glucagon. On the other hand, Maeda et al. (12) showed that glucagon only enhances intracellular cAMP levels in initial parts of the IMCD.
A great number of studies have been done since then that have shown the effect of this hormone on the different parts of the nephron in an attempt to elucidate its mechanisms of action. It was demonstrated that glucagon inhibits water, Na, Cl, K, Ca, and P reabsorption in proximal convoluted tubules (3, 8) , stimulates Na, Cl, K, Mg, and Ca (5) reabsorption in the thick ascending limb (10) , enhances the glomerular filtration rate (17, 18) , and stimulates bicarbonate secretion in distal tubules and collecting ducts (13) .
More recently, many studies have revealed that ingestion of a protein meal or an amino acid infusion stimulates glucagon release (11, 14, 16) and enhances urea excretion and water reabsorption (Ref. 1 , and see review in Ref. 6) , demonstrating that this hormone may participate in the mechanism of urine concentration and in the handling of urea and water by the kidney.
Despite the large number of studies carried out to examine the effect of glucagon on each nephron segment, its effect on water transport in the IMCD remains unclear. The purpose of the present study was to investigate the role of glucagon in this final segment and to try to elucidate its mechanism of action. The results showed that glucagon was able to increase cAMP production, increasing the AQP2 expression and water reabsorption.
METHODS
The animals used were male Wistar rats, weighing 120 -150 g, obtained from the animal facility of the University of São Paulo. They were housed and maintained under standard laboratory conditions with a pattern pellet diet and tap water ad libitum.
This research was approved by the Ethical Committee from Medical School of the University of São Paulo-CAPPesq-FMUSP.
Isolated Microperfusion Experiments
IMCD were dissected and isolated carefully, by a previously described technique (2, 20) , from a small slice immersed in a dish of chilled Ringer/HCO3 buffer, oxygenated, and kept at pH 7.4 by bubbling the solution with 5% CO 2 and 95% O2 for 30 min. The inner third sections (IMCD 3) were isolated from the terminal two-thirds of the last segment (21) . The bathing solution contained 115.0 mM NaCl, 25.0 mM NaHCO 3, 10.0 mM Na acetate, 5.0 mM KCl, 1.0 mM CaCl 2, 1.2 mM MgSO4, 1.2 mM NaH2PO4, and 5.5 mM glucose. The solution was equilibrated with 95% O 2/5% CO2 at 37°C and the pH was adjusted to 7.4. The measured osmolality was 285 Ϯ 2 mosmol/kg H 2O. The perfusate was hypotonic (70 -75 mosmol/kg H 2O) compared with the bath solution with the withdrawal of NaCl. To produce the osmotic gradient, these levels of osmolality were chosen to avoid extracellular hyperosmolality, which is known to alter several transport processes. The vital dye FD&C green was added to the perfusate as a visual marker.
The tubules were mounted between two concentric pipettes, as described previously (2, 20) and bathed at 37°C. At determined intervals, the collected fluid was removed with a calibrated sampling pipette, and the mean duration of the collection periods was 10 min.
Net water absorption (Jv) was measured with [ 14 C]inulin dialyzed immediately before the experiments. The dialyzed isotope was added to the perfusion solution to give a final concentration of 25-100 counts ⅐ min Ϫ1 ⅐ nl Ϫ1 . No leakage of radioactive inulin into the bath fluid was detected. Jv was calculated as Vi Ϫ Vo/l, where Vi is the perfusion rate, Vo is the collecting rate, and l is the tubule length in millimeters (tubular length and inside diameter can be measured to within 0.05 mm with a precalibrated micrometer adapted on the eyepiece of an inverted microscope). Vo was directly measured using the collection pipette, whereas Vi was calculated as Vi ϭ Vo (Ino/Ini), where Ino is [
14 C]inulin cpm/nl of the collected fluid and Ini is 14 C cpm/nl of the perfusate. Timed tubular samples were collected for analysis under mineral oil by aspiration into a calibrated pipette. All measurements were made 60 -90 min after the onset of perfusion of a given nephron segment. The internal diameter (id) of the perfused segments ranged from 20 to 30 m and the duct length (l) from 1.0 to 2.0 mm. The area was calculated as id ϫ ϫ l, expressed as 10 Ϫ4 cm 2 . Osmotic permeability. Osmotic permeability (Pf) was determined by measuring the net fluid movement in response to an imposed osmotic gradient. Perfusion rates of 20 to 30 nl/min were used to avoid osmotic equilibrium between perfusate and bath. Pf was calculated for each sample by standard methods and equations (2) .
Perfusate and bath fluid were checked for sodium and potassium concentration, for osmolality, and for pH by using a Na-K flame photometer (model 143, Instrumentation Laboratory, Lexington, MA), an osmometer (Advanced Instruments), and a pHmeter (Iris 7 Tecnow SP, Brazil). respectively.
The bath fluid was changed every 10 min to reduce the effect of the evaporation and consequently the increase in osmotic gradient. The bath osmolality did not change significantly during a 10-min period (from 284 Ϯ 1 at 0 min to 287 Ϯ 1 at 10 min).
Timed fluid collections were made with a constant volume constriction pipette. The fluid collected was rinsed four times in a vial containing 0.5 ml of water and 5 ml of scintillation liquid. Isotope concentration was determined with a liquid scintillator analyzer (Packard, model 1600 TR). A minimum of three collections were made. Pf was determined for each collection, and the reported values for a given experimental period were calculated as averages of the individual collections made during that period.
Determination of cAMP
Cell preparation. Fresh suspensions of IMCD cells from 10 papillae for control and 10 for Gl were prepared. The distal parts of the papilla were excised from the kidney and immediately placed in a vial containing ice-cold HEPES Ringer solution (in mM: 118 NaCl, 16 HEPES, 14 glucose, 3.2 KCl, 2.5 CaCl2, 1.8 MgSO4, 1.8 KH2PO4, pH 7.4) and finely minced. The pieces were disaggregated by incubation in the same solution with 0.2% collagenase (Sigma) in a shaking water bath constantly gassed with room air for 75 min at 37°C. After 45 min of incubation, 0.001% DNAase (Sigma) was added, and the cells were aspirated through a Pasteur pipette 12 times to softly shake the sample over a 15-min period. The suspension was then subjected to a separation procedure, which consisted of three steps of low-speed centrifugation (28 g for 2 min). After this final step of cell purification, the pellet containing IMCD cells was suspended in the Ringer bicarbonate solution.
cAMP production assay. The final pellet of IMCD cells, containing 200 -300 g/ml of protein, was separated and placed in two vessels and preincubated 5 min at 37°C with IBMX. The reaction was then started by the addition of glucagon 10 Ϫ7 M and Ringer bicarbonate solution as control. After at least 30 min of incubation at 37°C, the reaction was stopped by freezing and quickly warming the vessels. The cAMP production of each vessel was measured with Biotrack cAMP direct enzymeimmonoassay from Amersham Pharmacia Biotech.
Protein Isolation and Western Blotting
Based on the microperfusion and cAMP results, another series of experiments to determine AQP2 expression in the luminal membrane fraction from IMCD was performed.
Renal medullas from normal kidneys were separated, and strips from these medullas were dissected in the same ice-cold solution used in the microperfusion experiments. These strips were incubated with 10 Ϫ7 M glucagon at 37°C, and the solution was bubbled with 5% CO2 and 95% O2 for at least 30 min. The control medullas were incubated in the same fashion without glucagon.
Electrophoresis and Immunoblotting
Preparation of membrane fractions. Medullary strip samples were homogenized in an ice-cold isolation solution (in mM: 200 Mannitol, 80 Hepes, 41 KOH, pH 7.5) containing protease inhibitors (cocktail protease inhibitor, Sigma) by using a Teflon pestle glass homogenizer (Schmidt and Co, Frankfurt, Germany). The homogenates were centrifuged at low speed (2,000 g) for 15 min at 4°C to remove nuclei and cell debris. Subsequently, the supernatants were spun at 100,000 g for 1 h at 4°C (Beckman, rotor Ti70i) to produce a pellet containing membrane fractions enriched for both plasma membranes and intracellular vesicles. The pellets were suspended in isolation solution with protease inhibitors.
From four control rats and five experimental rats, samples of membrane fractions were run on 12.5% polyacrylamide gels for AQP2 (Hoefer SE 600 series, Electrophoresis Unit). After transfer by electroelution to nitrocellulose membranes (PolyScreen, PVDF Transfer, New Life Science), blots were blocked with 5% milk and 0.1% Tween 20 in phosphate-buffered saline (8.7 g/l NaCl, 7.2 mM dibasic phosphate, and 2.8 mM monobasic phosphate) for 1 h. Blots were then incubated with an anti-AQP2 antibody (1:2,000). The labeling was visualized with horseradish peroxidase (HRP)-conjugated secondary antibody (anti-rabbit IgG, diluted 1:2,000, Sigma) by using an enhanced chemiluminescence system (ECL, Amershan). To control for loading, blots were incubated with actin antibody (1:3,000, Santa Cruz Biotechnology, Santa Cruz, CA). The labeling was visualized with HRP-conjugated secondary antibody (anti-mouse IgG diluted 1:2,000, or anti-goat diluted 1:5,000; Sigma).
Quantification of kidney levels of AQP2. ECL films with bands within the linear range were scanned using Image Master VDS (Pharmacia Biotech). For AQP2, both the 29-and the 35-to 50-kDa bands (corresponding to nonglycosylated and glycosylated species) were quantified by densitometric analysis and normalized with densitometric actin protein abundance.
Statistics
All quantitative data are expressed as means Ϯ SE. Differences among the means of multiple parameters were analyzed by ANOVA followed by the Student-Newman-Keuls test. Differences between two parameters were analyzed by either unpaired t-test or by nonparametric methods (Mann-Whitney test). Values of P Ͻ 0.05 were considered significant.
Chemicals
Glucagon was purchased from Eli Lilly; synthetic arginine vasopressin and the others drugs were purchased from Sigma Chemical. The isotopic materials used were obtained from New England Nuclear (Boston, MA). The AQP2-specific antibodies, a peptide-derived polyclonal antibody, specific for the AQP2 water channel, was kindly supplied by Dr. Mark Knepper (National Heart, Lung, and Blood Institute, Bethesda, MD). Aquasol Universal LSC Cocktail (New England Nuclear) was used as a liquid scintillator. Glucagon and the others drugs used in microperfusion were diluted in bidistilled water.
RESULTS
Glucagon and all the drugs were added to the bath solution. The addition of glucagon to the perfusion fluid did not produce results.
Glucagon Effect
The first series of experiments tested the effect of 10 Ϫ7 M of glucagon in the absence of AVP.
In the first group (n ϭ 5), we measured the Pf in normal rats. The hormone increased Pf from 4.38 Ϯ 1.40 to 11.16 Ϯ 1.44 (P Ͻ 0.01). During the recovery period, after withdrawal of glucagon, the Pf decreased to low levels (5.51 Ϯ 1.41) (Fig. 1) .
In the second group of experiments (n ϭ 6), a dosedependent effect was observed after the addition of 10
Ϫ8
, 10 Ϫ7 , and 10 Ϫ6 M glucagon to the bath. Pf increased from 1.40 Ϯ 1.69, during the control period, to 3.11 Ϯ 1.41 (P Ͻ 0.05), 15.12 Ϯ 2.26 (P Ͻ 0.02), and 25.99 Ϯ 3.11 (P Ͻ 0.02), respectively (Fig. 1) .
cAMP Dosage
In the second series of experiments, the level of cAMP was determined in a fresh cell suspension from 10 rats in the presence of 10 Ϫ7 M of glucagon. The cAMP in the basal level was 1.24 Ϯ 0.39 fm/mg protein and enhanced to 59.70 Ϯ 15.18 in the presence of glucagon. The results were statistically different (P Ͻ 0.001) from the control value.
Experiments with Antagonist
In the third series of experiments, the effect of substances that inhibited the action of glucagon and vasopressin was tested (Fig. 2) .
PKA inhibitor: H8 effect. In another group (n ϭ 5), the protein kinase A inhibitor N-(2-[methylamino]ethyl)5-isoquinolinesulfonamide or H8 (10 Ϫ6 M) was able to inhibit the action of glucagon, i.e., the Pf was decreased when H8 was added before or after the hormone, control, 3.25 Ϯ 0.56; Gl 14.98 Ϯ 1.41 (P Ͻ 0.02); Gl ϩ H8 1.84 Ϯ 0.85 (P Ͻ 0.02); Gl 11.73 Ϯ 3.11 (P Ͻ 0.02) and control 3.11 Ϯ 1.13; H8 1.84 Ϯ 0.71; H 8 ϩ Gl 2.26 Ϯ 0.56; H8 2.26 Ϯ 0.85.
Glucagon Antagonist Effect
On glucagon action (n ϭ 5). In the presence of the glucagon antagonist, des-His 1 -[Glu 9 ]glucagon amine (AGl), the water permeability enhanced with glucagon was blocked either when the inhibitor was added before or after glucagon, control 1.84 Ϯ 0.42; Gl 9.89 Ϯ 0.84 (P Ͻ 0.05); Gl ϩ AGl 2.12 Ϯ 0.71 (P Ͻ 0.05); GL 9.04 Ϯ 0.99 (P Ͻ 0.05) and control 1.98 Ϯ 0.14; AGl 1.98 Ϯ 0.14; AGl ϩ Gl 1.97 Ϯ 0.28; AGl 1.5 Ϯ 0.14, respectively. On the other hand, when this antagonist was added in the presence of AVP (10 U/ml), it was not able to block this hormone, control 2.40 Ϯ 0.56; AVP 104.98 Ϯ 13.14 (P Ͻ 0.01); AVP ϩ AGl 108.40 Ϯ 13.84; AVP 110.92 Ϯ 13.56 and control 2.12 Ϯ 0.42; AGl 2.26 Ϯ 0.28; AGl Ϯ AVP 118.27 Ϯ 10.31 (P Ͻ 0.01); AGl 3.11 Ϯ 0.56 (Fig. 2) .
Combined Effect
AVP (10 U/ml) was tested with 10 Ϫ7 M of glucagon and a combined effect was observed (n ϭ 5), control 2.40 Ϯ 0.71; glucagon (10 Ϫ7 M) 23.31 Ϯ 5.79 (P Ͻ 0.02); glucagon ϩ AVP (10 U/ml) 106.01 Ϯ 19.21(P Ͻ 0.01); glucagon 31.93 Ϯ 8.05. When ADH was put before glucagon (n ϭ 5), this effect was not observed: control 1.98 Ϯ 0.14; ADH 116.40 Ϯ 30.52(P Ͻ 0.01); ADH ϩ glucagon 117.98 Ϯ 33.06; ADH 115.27 Ϯ 35.46. Probably, in this second set of experiments, even a low dose of AVP was able to mask the glucagon effect (Fig. 2) . Ϫ7 , and 10 Ϫ6 M glucagon (n ϭ 6). Lines connect data points for each experimental groups. Significant difference: crosses ϭ P Ͻ 0.01; &P Ͻ 0.02; *P Ͻ 0.05.
Immunoblotting Studies AQP2 Expression
Fresh tubule suspensions of IMCD were incubated for at least 30 min with 10 Ϫ7 M of glucagon. Four rats were used for the control group and five rats for the experimental group. The immunoblotting studies showed that, in absence of AVP, glucagon increased both the 29-kDa and the 35-to 50-kDa bands corresponding to the nonglycosilated and glycosilated AQP2, respectively. The densitometric analysis of the immunoblotting assays showed an increase in AQP2 protein abundance of ϳ27% compared with the control 100.0 Ϯ 3.9 vs. glucagon 127.53 Ϯ 53 (P Ͻ 0.05) (Fig. 3) .
These data reveal a close correlation between the increase in the AQP2 expression and the microperfusion results.
DISCUSSION
In experiments based on clearance and on isolated tubule microperfusion techniques (18, 19, 22, 23, 24) , it has been demonstrated that glucagon participates in the regulation of ions and water excretion by the kidney. However, no study has been conducted thus far to directly evaluate the effect of glucagon on water transport in isolated microperfused IMCDs. The experiments reported here show that glucagon was able to enhance the water reabsorption, the cAMP production, and the AQP2 abundance in the above-mentioned segment.
Effect of Glucagon on Water Reabsorption
In the first series of experiments, the Pf and the doseresponse curve were determined, showing a direct effect of glucagon on water reabsorption in AVP absence. The first group shows the effect of 10 Ϫ7 M glucagon on Pf. This dose was chosen because it was the lowest dose that caused a reproducible effect, even though Di Stefano et al. (13) In micropuncture and other studies, the dose used varied widely (7, 8, 12, 13, 15, 18, 19, 28) .
The increase in the water transport after glucagon addition to the bath is in accordance with the data demonstrated by Ahloulay et al. (18, 19) who showed, through a clearance experiment, that water conservation occurred in glucagoninfused rats. An opposite effect on proximal convoluted tubules, i.e., water and NaCl transport inhibited by glucagon, was shown by Rouffignac et al. (12) . However, it is well known that, in this segment, water is transported by a passive process, depending on the osmotic pressure difference established by the solute transport, principally sodium. In this segment, glucagon inhibits Na and Pi reabsorption and, consequently, water absorption. The Pf values found in our experiments are lower than the stimulated-vasopressin Pf already reported for this segment (20, 21) , showing that glucagon does not have the same efficiency as AVP, certainly because glucagon is not the principal hormone involved in water absorption.
To demonstrate a dose-dependent effect, 10
Ϫ8
, 10 Ϫ7 , and 10 Ϫ6 M were used. In Fig. 1 , this effect can be observed, and despite the fact that only three doses were used, a dosedependence effect was readily apparent.
Effect of Glucagon on cAMP Production
Since 1958 (4), it has been known that glucagon stimulates cAMP in hepatocytes, and in 1976 (5) it was demonstrated that the glucagon effect may be mediated by cAMP in renal medulla. Although it has been already observed that there are receptors for glucagon in the nephrons (7) and specifically in the distal nephrons (6), Maeda et al. (8) were not able to prove the production of cAMP by this hormone in microdissected IMCD, but Briffeuil et al. (9) did not demonstrate any action of glucagon when it was infused directly in the renal artery in an anesthetized dog. To understand our data in the microperfusion experiments, the production of cAMP was determined in the presence of glucagon and in the absence of AVP, using freshly microdissected tubules. These assays showed that, in IMCD, 10 Ϫ7 M glucagon increased the intracellular level of cAMP after incubation by at least 30 min. Other researchers have already demonstrated the cAMP production by glucagon, but with different preparations (11, 29, 30) .
It is well known that this second messenger is present in all the cells that contain the receptor-Gs protein-adenylyl cyclase complex, and, depending on the hormone, the effect produced is different in each type of cell. In the IMCD cells, the vasopressindependent cAMP will stimulate the water transporter, but the role of the glucagon-stimulated cAMP in this transporter had not been identified previous to this present study.
Since the final effect we observed was the increase in water absorption, the first conjecture was that glucagon could be stimulating the mechanism responsible for the water transport in this segment. This idea led us to consider different hypotheses concerning the glucagon action. This hormone could be 1) stimulating its own receptor to produce cAMP and crosstalking with the vasopressin cascade, directly stimulating the PKA and all the reactions from this point and consequently enhancing the water permeability; 2) cross-talking directly with the vasopressin receptor, stimulating cAMP production, and triggering all the cascade, starting at the beginning; or 3) stimulating another receptor and/or another pathway not yet identified.
To investigate these hypotheses, employing the microperfusion technique, the following experiments were carried out.
Effect of Glucagon Antagonist and Vasopressin Inhibitor
Glucagon antagonist: glucagon. The antagonist des-His 2 [Glu 9 ] glucagon amide is the same glucagon molecule without the initial histidine (31). Its action was described by Post et al. (32) who showed that the antagonist interacts with the glucagon receptor coupled with adenylyl cyclase, and Unson et al. (31) already previously identified this peptide as a full glucagon antagonist at receptors on hepatocyte membranes. The results we obtained showed an abrupt fall in the glucagon-stimulated Pf in the presence of this antagonist and the incapacity of glucagon to increase the Pf when the anti-glucagon was added to the bath first, i.e, before the glucagon was added. This fact showed that the antagonist could occupy the receptor and block the glucagon action. Although the interaction between peptide hormones and their receptors have not been yet fully understood, our data showed strong evidence that glucagon is stimulating its own receptor.
Vasopressin. When the effect of the glucagon antagonist on the action of AVP was analyzed, the results revealed that AVP was not inhibited in both situations when added before and when added after the hormone. This fact shows that probably it did not occupy the AVP receptor, confirming the idea that glucagon is acting via its own receptor.
Protein kinase A inhibitor-H8. To investigate whether glucagon transports water by stimulating protein kinase A, H8 was used, and our results showed that H8 fully inhibited the effect of glucagon when added before or after the hormone, demonstrating that the mechanisms used by glucagon to increase the water absorption include the stimulation of PKA. This data reinforces the above-mentioned results. On the other hand, recently we published results (25) showing that glucagon is able to stimulate PKC, producing a decrease in UT-A1 expression. This contrast of action of the same hormone in the same cell is in agreement with the results shown by the articles of Alouhlay (1) .
Combined actions. In these experiments, we tried to show a synergic effect between glucagon and AVP. When AVP was added before glucagon, even only when 10 U/ml of AVP was used, this small amount was able to mask the glucagon effect. These results showed that AVP was probably able to stimulate cAMP production maximaly, not allowing an additional glucagon effect. On the other hand, when glucagon was assayed before AVP, an increase beyond the glucagon Pf-stimulated was observed. The use of AVP in concentrations below 10 U/ml did not provide stable results, compromising the demonstration of a total synergic effect between glucagon and AVP.
Effect of Glucagon on Aquaporin 2 Expression
The AQP2 expression was increased when IMCDs were incubated with glucagon for at least 30 min, confirming that the glucagon-stimulated cAMP was able to trigger protein kinase A and probably the subsequent steps to increase the AQP2 expression abundance in IMCDs.
In summary, our data showed that, in microperfused IMCDs from normal rats, glucagon was able to stimulate the synthesis of cAMP, leading us to suppose that this cAMP is the second messenger responsible for enhancing water reabsorption, providing evidence of an uncommon cross-talking phenomenon between the glucagon mechanism and the vasopressin cascade. In addition, these experiments provide more knowledge about the mechanism whereby glucagon enhances water absorption, contributing to understanding the role of this hormone in the water conservation mechanisms. Our results are in agreement with findings cited in the literature, which showed that glucagon participates in the kidney's water handling.
